Together4Cancer

🚨 400+ oncology papers are published every day. Most never reach community practice. At Together4Cancer, I filter the flood of research to bring community oncology leaders: ✅ Evidence-based insights you can use today ✅ Best practices worth amplifying ✅ Early signals that…

In PhALLCON phase 3, ponatinib outperformed imatinib in newly diagnosed Ph+ ALL—not only in efficacy but also in patient-reported tolerability and HRQoL, with clinical response driving better quality of life. This underscores ponatinib’s holistic benefit—key for community…

KEYNOTE-585 final analysis reinforces perioperative pembrolizumab + chemo in resectable gastric/GEJ cancer—median OS improved to 71.8 vs 55.7 months (HR 0.86), with better event-free survival and stable QoL. Safety comparable to chemo alone. Explore this pivotal data shaping…

PhALLCON phase 3 data show ponatinib not only improves remission rates in newly diagnosed Ph+ ALL but also enhances HRQoL compared to imatinib—driven by better tolerability and sustained response. For community oncologists optimizing frontline therapy, this invites a fresh look…

PhALLCON’s phase 3 data in newly diagnosed Ph+ ALL show ponatinib not only drives superior clinical responses but also enhances HRQoL via better tolerability and sustained remission versus imatinib. This underscores integrating patient-reported outcomes when optimizing frontline…

Targeted indoor residual spraying in Merida cut indoor Aedes aegypti density by 59% but didn’t significantly reduce symptomatic chikungunya, dengue, or Zika in children. A modest 24% community-level case drop emerged, highlighting complexities in vector control efficacy. Delve…

PhALLCON confirms ponatinib’s edge over imatinib in newly diagnosed Ph+ ALL: superior clinical response links to meaningful HRQoL gains, while tolerability directly impacts patient well-being. A must-read to optimize therapy decisions balancing efficacy and quality of life in…

KEYNOTE-585 final analysis shows perioperative pembrolizumab + chemo in resectable locally advanced gastric/GEJ cancer extends median OS to 71.8 vs 55.7 months (HR 0.86), with improved EFS and stable QoL. Safety is comparable to chemo alone. A pivotal read for refining periop…

Final analysis of KEYNOTE-585 affirms adding pembrolizumab to perioperative chemo in resectable locally advanced gastric/GEJ cancer improves median OS (71.8 vs 55.7 months; HR 0.86) and EFS (HR 0.81) without compromising QoL or increasing severe toxicity. Worth deep dive for…

ROME trial provides first-of-its-kind, randomized phase 2 evidence that tumor-agnostic, genomically-matched therapies - chosen by multidisciplinary molecular tumor boards - can significantly improve response rates and progression-free survival compared with standard care for…

Monday I met a new patient with metastatic PDAC. He met his community oncologist last Wed, got cfDNA & referred to us for trial. Today found he has KRAS G12D. He will get 1L line with chemo + G12D inhib. My colleague made all the difference in this patient care🙏Team work!

Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer annalsofoncology.org/article/S0923-…

Frailty assessment is an essential step in modern oncology - choosing regimens that maximize survival and quality of life while minimizing preventable toxicity, hospitalizations, and loss of independence. A good read: doi.org/10.1080/104281… #mmsm, #multiplemyeloma,…

AI-augmented LDCT screening is reshaping lung cancer detection - enabling concurrent lung nodules, emphysema, and cardiovascular risk assessment from one scan. The approach turns community LDCT programs into true population health engines, improving early detection, streamlining…

I think a big problem here is that medical school only exposes people to inpatient oncology, which is a wildly different (and sadder) world from outpatient oncology- which is like 90% of cancer care. So students have an incorrect idea of what practicing oncology is like.

“Managing anemia in low risk MDS” review article (+ Rx algorithm 👇) by @Dr_AmerZeidan @FiekeHoff @madanatyazan in @JCO_ASCO: - Imetelstat is now part of the algorithm (IMerge Ph III, approved last year in June), along with ESA, Len, and Luspatercept! #HemeTwitter #OncTwitter

🫁 1L immunotherapy vs targeted therapy in BRAFV600E-mut NSCLC (FRONT-BRAF). In BRAFV600E-mutated metastatic NSCLC, first-line immunotherapy (± chemo) improved OS vs BRAF+MEK inhibitors (40.9 vs 25.2 mo). Benefit was greater in PD-L1 ≥1%, TP53 co-mut, smokers, and ≥70y. 📖…

Excellent @BloodCancerJnl myeloma work by @chngwj et al 👏 In NDMM, cyclophosphamide probably doesn't add much (e.g., Bridoux JCO 2020: VCd ≈ Vd if cast nephropathy)... But in RRMM, Cy can carry a punch! Pom-dex has defeated many a drug in #MMsm trials, but not Pom-Cy-Dex 💪🏻

- 02/2025: 8 ADC phase 3 trials promise to change practice by the end of the year - 10/2025: 6/8 are positive ✅

🚨 Hot off the press in @ASCO journal @JCOOA_ASCO 👉Pleased to share our study 👉 "Impact of FDA Project Optimus Guidance on Design of Early-Phase Clinical Trials" 📊 Analysis of 367 phase I #oncology trials (2021-2024) reveals Project Optimus is transforming cancer drug…

Pediatric medical imaging radiation shows a clear dose-dependent increase in hematologic cancer risk—up to 3.6-fold at 50-100 mGy. In a cohort of 3.7M children, ~10% of these cancers linked to imaging exposure. Essential read for balancing diagnostic benefits versus long-term…